Prophylactic Ketorolac Post Epiretinal Membrane Surgery

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. Since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen's University
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• idiopathic epiretinal membrane diagnosis requiring membrane peel surgery

Exclusion Criteria:

• proliferative diabetic retinopathy

• sickle cell retinopathy

• radiation retinopathy

• choroidal folds

• hypersensitivity or allergy to NSAIDs

• wet macular degeneration

• branch retinal vein occlusion (BRVO)

• central retinal vein occlusion (CRVO)

• complicated membrane peel surgery